# BEAT (BEAT)

> Source: Nexqual · https://nexqual.com/BEAT · data as of 2026-10-15 20:00 UTC · cite as "Nexqual, BEAT (BEAT), nexqual.com/BEAT" · informational, not investment advice.

**Price:** USD 0.43 (+9.82% on the day) · last close of Oct 15, 2026; US market closed, not a live price. Prev close 0.43 · day 0.4–0.44 · 52w 0.36–4 · market cap null · NCM

## Key facts
- Total return with dividends: 1Y -75.0% vs S&P 500 +18.1%; 5Y -89.8% vs S&P 500 +85.1%.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Operating income | -$2.3M | -$13.0M | -$15.3M | -$19.9M | -$21.1M | -$20.4M |
| Net income | -$4.4M | -$13.0M | -$14.6M | -$19.4M | -$21.0M | -$20.3M |
| EPS (diluted) | -$1.03 | -$1.59 | -$0.72 | -$0.73 | -$0.62 | — |
| Free cash flow | — | -$9.9M | -$12.3M | -$14.7M | -$14.6M | -$14.0M |
| Cash + short-term investments | $13.2M | $3.6M | $16.2M | $2.4M | $4.4M | — |
Fiscal years end Dec. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)


## Total return (dividends reinvested)
|  | 1Y (from 2025-10-16) | 5Y (from 2021-11-08) |
|---|---|---|
| Total return | -75.0% | -89.8% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -75.2% | -37.1% |
| Volatility (annualized) | 150.6% | 109.1% |
| Max drawdown | -89.5% (Dec 2025→Sep 2026) | -93.8% (Oct 2022→Sep 2026) |

## Peers
ATRC (AtriCure, Inc.) USD 57.78 +1.60% · SUPN (Supernus Pharmaceuticals, Inc.) USD 39.57 -5.81% · KALA (KALA BIO, Inc.) USD 0.19 -26.08% · INGN (Inogen, Inc) USD 6.3 -0.71% · VNDA (Vanda Pharmaceuticals Inc.) USD 4.24 -1.40%

## More
Full page: https://nexqual.com/BEAT · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt